Notice of Application - 2013
[Federal Register Volume 78, Number 35 (Thursday, February 21, 2013)]
[Notices]
[Page 12102]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-03892]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Mallinckrodt, LLC
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on November 30, 2012,
Mallinckrodt, LLC, 3600 North Second Street, St. Louis, Missouri 63147,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as a bulk manufacturer of the following basic
classes of controlled substances:
| Drug |
Schedule |
| Tetrahydrocannabinols (7370) |
I |
| Codeine-N-oxide (9053) |
I |
| Dihydromorphine (9145) |
I |
| Difenoxin (9168) |
I |
| Morphine-N-oxide (9307) |
I |
| Normorphine (9313) |
I |
| Norlevorphanol (9634) |
I |
| Amphetamine (1100) |
II |
| Methamphetamine (1105) |
II |
| Methylphenidate (1724) |
II |
| Nabilone (7379) |
II |
| 4-Anilino-N-phenethyl-4-piperidine (8333) |
II |
| Codeine (9050) |
II |
| Dihydrocodeine (9120) |
II |
| Oxycodone (9143) |
II |
| Hydromorphone (9150) |
II |
| Diphenoxylate (9170) |
II |
| Ecgonine (9180) |
II |
| Hydrocodone (9193) |
II |
| Levorphanol (9220) |
II |
| Meperidine (9230) |
II |
| Methadone (9250) |
II |
| Methadone intermediate (9254) |
II |
| Dextropropoxyphene, bulk (non-dosage forms) (9273) |
II |
| Morphine (9300) |
II |
| Oripavine (9330) |
II |
| Thebaine (9333) |
II |
| Opium tincture (9630) |
II |
| Opium, powdered (9639) |
II |
| Oxymorphone (9652) |
II |
| Noroxymorphone (9668) |
II |
| Alfentanil (9737) |
II |
| Remifentanil (9739) |
II |
| Sufentanil (9740) |
II |
| Fentanyl (9801) |
II |
The firm plans to manufacture the listed controlled substances for
internal use and for sale to other companies.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 22, 2013.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-03892 Filed 2-20-13; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO). |
